NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 6 நாட்களுக்கு முன்இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Sharda Cropchem Q2 PAT Rises 23% to ₹92 Cr; Reaffirms FY27 Capex of ₹550-600 Cr
Sharda Cropchem reported its Q2 FY27 earnings call details, registering a 13% YoY growth in revenue to ₹1,052 Cr and a 23% YoY rise in PAT to ₹92 Cr. Revenue expansion was driven by price increases, favorable forex, and product mix (+18.3%), which offset a volume decline of 5.1%. Growth was led by strong performance in NAFTA (+30% YoY) and LATAM (+80% in agrochemicals), while Europe softened due to extended heat and drought. Management retained its FY27 revenue growth guidance of 10-15%, expected EBITDA margins of 18-20%, and planned registration capex of ₹550-600 Cr.
உச்சம் நம்பிக்கை
என்ன மாறியதுSubmission of the formal transcript for the Q2 FY27 earnings conference call held on November 02, 2026.
ஏன் இது முக்கியம்Clarifies management's margin levers (pricing, product mix) against underlying volume headwinds and details European restocking delays alongside planned registration capex.
Q2 FY27 Revenue: ₹1,052 கோடிQ2 FY27 PAT: ₹92 கோடிEBITDA லாப வரம்பு: 15.6%Cash & Liquid Investments: ₹846 கோடிPlanned FY27 Capex: ₹550-600 CrFY27 Capex vs Net Worth: ~18.2% to 19.9%
📅 குறுகிய காலம்Stable to slightly positive as strong margin delivery in NAFTA and LATAM counteracts volume softness and European weather headwinds.
📈 நீண்ட காலம்Structural growth remains intact driven by an asset-light, registration-heavy model with over 3,044 registrations and a strong pipeline of 946 applications.
⚠ அபாய எச்சரிக்கைகள்
Negative volume growth of -5.1% in Q2
Adverse weather impacts in Europe leading to distributor destocking
Elevated freight/transportation costs weighing on non-agro margins
👀 கவனிக்க வேண்டியவை
Track Europe's demand recovery during the seasonally stronger second half (H2) and monitor if volume growth turns positive to support full-year revenue guidance.
Sharda Cropchem Q2 FY27 PAT Rises 23% YoY to ₹92 Cr; Revenue Up 13% to ₹1,052 Cr
Sharda Cropchem reported a 13% YoY increase in consolidated revenue to ₹1,052 crore for Q2 FY27, driven by strong growth in NAFTA and LATAM regions compensating for a 7% decline in European agrochemicals. EBITDA expanded by 18% YoY to ₹164 crore, with margins improving 70 bps to 15.6%, while PAT rose 23% YoY to ₹92 crore. The company maintained its debt-free balance sheet with cash and liquid investments of ₹846 crore, after deploying ₹419 crore in capex during H1 FY27 for product registrations. Management maintained its full-year FY27 revenue growth guidance of 10–15% and expects EBITDA margins to reach 18–20%.
உச்சம் நம்பிக்கை
என்ன மாறியதுRelease of Q2 and H1 FY27 financial performance along with management guidance confirming 10–15% FY27 top-line growth.
ஏன் இது முக்கியம்Demonstrates resilience in the asset-light generic registration model, as expansion in NAFTA (+30%) and LATAM (+81%) effectively cushioned weather-related softness in core European markets.
📅 குறுகிய காலம்Operating margins and profit growth support positive market sentiment, though distributor destocking in Europe remains a key near-term monitorable.
📈 நீண்ட காலம்Consistent registration additions (reaching 3,044 with 946 in pipeline) sustained by internal accruals strengthen global market access without balance sheet leverage.
⚠ அபாய எச்சரிக்கைகள்
Weather and drought-induced distributor destocking in central and eastern Europe
Forex volatility impacting realisations across international operations
High dependence on third-party supply chain and contract manufacturers
👀 கவனிக்க வேண்டியவை
Track European channel restocking and demand recovery in H2 FY27 (seasonally the stronger half), along with progress towards meeting the 18–20% full-year EBITDA margin guidance.
Sharda Cropchem approved its standalone and consolidated unaudited financial results for the quarter and half-year ended September 30, 2026. The statutory auditors B S R & Co. LLP issued a Limited Review Report with an unmodified opinion. In the standalone H1 FY27 cash flow statement, net cash generated from operating activities stood at ₹478.03 crore compared to ₹584.31 crore in H1 FY26. Standalone closing cash and cash equivalents rose to ₹191.29 crore as of September 30, 2026, up from ₹78.54 crore a year prior.
உச்சம் நம்பிக்கை
என்ன மாறியதுFormal approval and submission of Q2 and H1 FY27 financial results along with the auditor's limited review report.
ஏன் இது முக்கியம்Provides visibility on half-yearly operating cash generation and sustained capital expenditure toward product registrations, which drive Sharda Cropchem's asset-light business model.
📅 குறுகிய காலம்Market focus will shift to top-line performance, gross margin trends, and geographic revenue contribution in Europe and NAFTA for Q2.
📈 நீண்ட காலம்Continued strong allocation toward intangible assets (product registrations) supports the pipeline of generic molecule rollouts in regulated markets.
⚠ அபாய எச்சரிக்கைகள்
Lower operating cash flow YoY in H1 FY27 due to working capital swings
Dependency on regulatory approvals and third-party manufacturing
👀 கவனிக்க வேண்டியவை
Track the full consolidated P&L metrics once detailed tables are released to assess revenue growth and operating margins against agrochemical sector peers.
9% Revenue Growth in Q1 FY27; EBITDA Rises 25% Despite European Softness
Sharda Cropchem reported a 9% YoY revenue growth to ₹1,074 Cr for Q1 FY27, supported by strong performance in LATAM and NAFTA. EBITDA grew 25% to ₹178 Cr as margins expanded by 220 bps to 16.6%, driven by a favorable product mix. However, PAT was impacted by significantly lower forex gains of ₹7.5 Cr compared to ₹73.1 Cr in the previous year. Management maintained its FY27 revenue growth guidance of 10-15% and highlighted a robust registration pipeline of 1,027 pending applications.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company started FY27 with improved operational margins and a stronger cash position, despite a high base in Europe and significantly lower non-operating forex gains.
ஏன் இது முக்கியம்The results validate the company's asset-light, registration-led model, showing that growth in LATAM and NAFTA can offset regional downturns while maintaining a debt-free balance sheet.
Q1 வருவாய்: ₹1,074 கோடிEBITDA Growth: 25%Forex Gain (Q1 FY27 vs Q1 FY26): ₹7.5 Cr vs ₹73.1 CrCash & Liquid Investments: ₹767 கோடிFY27 Revenue Guidance: 10-15%Cash vs Market Cap: ~10.1%
📅 குறுகிய காலம்Operational momentum is positive with margin expansion; however, the sharp drop in net profit due to forex translation may cause short-term price volatility.
📈 நீண்ட காலம்The structural growth story remains intact as the company continues to invest ₹450-500 Cr annually in registrations, building a high-entry-barrier moat in regulated markets.
👀 கவனிக்க வேண்டியவை
Monitor the recovery in the European market, which saw temporary softening due to heatwaves, and track the conversion of the 1,027 pending registrations into revenue-generating products.
Sharda Cropchem Q1 FY27: EBITDA up 25% to ₹178 Cr; NAFTA & LATAM Offset Europe Weakness
Sharda Cropchem reported a 9% YoY revenue growth to ₹1,074 Cr for Q1 FY27, driven by robust performance in NAFTA (+33%) and LATAM (+52%) regions. While EBITDA grew 25% to ₹178 Cr with a 220 bps margin expansion to 16.6%, PAT fell 38% to ₹88 Cr due to a high base effect from forex gains in Q1 FY26. The company remains debt-free with ₹767 Cr in liquid investments and continues its asset-light strategy, investing ₹263 Cr in capex during the quarter. Management maintained its FY27 revenue growth guidance of 10-15%.
உச்சம் நம்பிக்கை
என்ன மாறியதுOperational EBITDA and margins showed strong growth despite a volume dip, and the company successfully diversified its revenue base toward NAFTA and LATAM to offset European climate headwinds.
ஏன் இது முக்கியம்The results validate the company's geographic diversification and registration-heavy model, showing that margin expansion is possible through product mix even when volumes are flat.
📅 குறுகிய காலம்The market is likely to view the operational EBITDA growth and margin expansion positively, looking past the optically lower PAT which was skewed by previous year's forex gains.
📈 நீண்ட காலம்The structural growth remains tied to the successful conversion of its massive registration pipeline into sales across regulated markets like NAFTA and Europe.
Negative volume growth in the core agrochemical segment
👀 கவனிக்க வேண்டியவை
Watch for volume recovery in the high-margin European market in upcoming quarters and the execution of the 1,027 pending registrations which drive the company's asset-light growth model.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Rs 263 Cr Capex in Q1 FY27; Global Registrations Reach 3,016
Sharda Cropchem reported a significant Q1 FY27 capex of Rs 263 Cr, representing approximately 51% of the total investing activities conducted in the entire previous fiscal year (FY26). The company's core asset base of global registrations has expanded to 3,016 across 80+ countries, supported by a pipeline of 1,047 pending applications. Financial performance in FY26 showed a strong recovery with revenue at Rs 5,267.6 Cr and PAT at Rs 681 Cr, following a loss-making FY24. The company maintains an asset-light model, focusing on IP development while outsourcing manufacturing to partners, primarily in China.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has significantly accelerated its investment in intellectual property, with Q1 FY27 capex nearly matching half of the previous year's total investment.
ஏன் இது முக்கியம்For Sharda's asset-light model, registrations are the equivalent of manufacturing capacity; this high capex signals aggressive future revenue potential and market share gains in the generic agrochemical space.
📅 குறுகிய காலம்The high capex intensity and recovery in margins are likely to be viewed positively by the market as it indicates management's confidence in the registration-led growth strategy.
📈 நீண்ட காலம்The structural shift toward generic agrochemicals as patents expire provides a long-term tailwind for Sharda's library of 3,000+ registrations.
⚠ அபாய எச்சரிக்கைகள்
High dependency on third-party manufacturers in China
Forex volatility affecting international revenue
Pricing pressure in the generic agrochemical segment
👀 கவனிக்க வேண்டியவை
Monitor the pace of new registration approvals in high-margin regulated markets like Europe and NAFTA, and track the impact of raw material sourcing costs from China on gross margins.
Sharda Cropchem Q1 FY27: Revenue up 9% YoY to ₹1,074 Cr, but PAT drops as margins compress
Sharda Cropchem reported a 9% YoY increase in consolidated revenue to ₹1,073.77 Cr for Q1 FY27. However, profitability faced significant headwinds as Profit Before Tax (PBT) declined 30% YoY to ₹118.43 Cr. The core Agrochemicals segment, which contributes ~85% of revenue, saw its segment result drop by 39.5% YoY to ₹82.32 Cr, indicating sharp margin contraction. Consolidated EPS for the quarter fell to ₹9.76 from ₹15.83 in the year-ago period.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company transitioned into the new fiscal year with volume-led revenue growth but suffered a significant decline in operating profitability and net margins.
ஏன் இது முக்கியம்The results highlight the vulnerability of Sharda's asset-light generic model to pricing pressure and product mix shifts, even when top-line growth is maintained. The 39.5% drop in agrochemical segment results is a material concern for short-term earnings quality.
📅 குறுகிய காலம்The stock is likely to react negatively in the short term due to the sharp contraction in margins and the year-on-year decline in PAT.
📈 நீண்ட காலம்While the registration-heavy model provides a long-term moat, the company's performance remains highly sensitive to global agrochemical pricing cycles and forex volatility.
⚠ அபாய எச்சரிக்கைகள்
Significant margin compression in core Agrochemicals segment
High seasonality affecting quarterly performance consistency
Limited pricing power in the generic agrochemical space
👀 கவனிக்க வேண்டியவை
Investors should monitor the recovery of margins in the Agrochemicals segment, which were impacted despite revenue growth. Key to watch is the management's commentary on pricing pressure in regulated markets like Europe and NAFTA, and the impact of seasonal weather patterns on the upcoming Q2 results.
Sharda Cropchem Recommends Final Dividend of Rs 9 Per Share for FY 2025-26
Sharda Cropchem Limited has announced a final dividend of Rs 9 per equity share for the financial year 2025-26. The recommendation was approved by the Board of Directors in their meeting on May 13, 2026. This dividend corresponds to a 90% payout on the face value of Rs 10 per share. The distribution is contingent upon shareholder approval at the next Annual General Meeting.
முக்கிய அம்சங்கள்
Final dividend recommended at Rs 9.00 per equity shareDividend payout is 90% of the face value of Rs 10.00Announced for the financial year 2025-26Subject to approval at the forthcoming Annual General Meeting
👀 கவனிக்க வேண்டியவை
Shareholders should hold the stock until the record date to qualify for the payout. Potential investors should evaluate the dividend yield against the current market price.
Sharda Cropchem Q4 FY26 PAT Jumps 57% to ₹319 Cr; EBITDA Surges 75%
Sharda Cropchem reported a robust performance for Q4 FY26, with consolidated revenue growing 13% YoY to ₹2,065 crore, primarily driven by volume growth in Europe and LATAM. The company's EBITDA surged by 75% to ₹513 crore as gross margins expanded significantly by 750 basis points to 37.3%. For the full year FY26, revenue reached ₹5,268 crore, marking a 22% increase, led by a 25% growth in the core agrochemical segment. The company continues to leverage its asset-light model, investing ₹505 crore in capex during FY26, largely for product registrations.
முக்கிய அம்சங்கள்
Q4 FY26 consolidated revenue increased 13% YoY to ₹2,065 Cr, with Agrochemicals contributing 93% of total sales.EBITDA for the quarter grew 75% YoY to ₹513 Cr, with EBITDA margins improving to 24.8%.Gross margins expanded by 750 bps to 37.3% in Q4, with management expecting these levels to sustain in FY27.Full-year FY26 revenue stood at ₹5,268 Cr, a 22% increase over the previous financial year.The company holds 3,011 global registrations with an additional 1,004 applications currently pending.
👀 கவனிக்க வேண்டியவை
Investors should view the significant margin expansion and strong volume growth in Europe as positive indicators of operational efficiency. The company's focus on an asset-light model and a growing registration pipeline supports long-term scalability, though the slight decline in NAFTA agrochemical revenue should be monitored.
Sharda Cropchem FY26 PAT Surges 124% to ₹681 Cr; Total Dividend at ₹15 Per Share
Sharda Cropchem reported a stellar performance for FY26, with annual revenue growing 22% to ₹5,268 crore and PAT more than doubling to ₹681 crore. The company's EBITDA margins saw a significant expansion from 14.2% to 19.7%, driven by improved product mix and volume growth in the agrochemical segment. A final dividend of ₹9 per share has been recommended, bringing the total FY26 payout to ₹15. The company maintains a debt-free balance sheet with a robust cash position of ₹702 crore and a record RoCE of 30.4%.
முக்கிய அம்சங்கள்
FY26 Net Profit (PAT) increased by 124% YoY to ₹681 crore, while Q4 PAT rose 57% to ₹319 crore.Consolidated EBITDA for FY26 grew 69% to ₹1,040 crore with margins expanding significantly to 19.7%.Agrochemical segment revenue grew 25% YoY in FY26, with Europe showing the strongest regional growth at 37%.Achieved highest-ever Return on Capital Employed (RoCE) of 30.4% and remains debt-free with ₹702 crore in liquid assets.Recommended a final dividend of ₹9 per share, taking the total FY26 dividend to ₹15 per share.
👀 கவனிக்க வேண்டியவை
The stock is expected to react very positively to the massive margin expansion and doubling of profits. Investors should monitor the company's ability to convert its 1,004 pending registrations into revenue as it continues its asset-light growth strategy.
Sharda Cropchem Recommends ₹9.00 Final Dividend and Approves FY26 Audited Results
Sharda Cropchem Limited has announced its audited financial results for the year ended March 31, 2026, alongside a final dividend recommendation of ₹9.00 per share. The company's 26 subsidiaries showed robust performance, contributing ₹2,80,239 lakhs in revenue and ₹21,070 lakhs in net profit. The statutory auditors, B S R & Co. LLP, have issued a clean audit report with no qualifications. This announcement reflects stable financial health and a commitment to shareholder returns.
முக்கிய அம்சங்கள்
Recommended a final dividend of ₹9.00 per equity share of ₹10.00 face value.Subsidiaries contributed a total revenue of ₹2,80,239 lakhs for the financial year.Net profit after tax from subsidiaries reported at ₹21,070 lakhs.Total assets across 26 audited subsidiaries amounted to ₹1,67,737 lakhs.Statutory auditors issued an unqualified opinion on both standalone and consolidated results.
👀 கவனிக்க வேண்டியவை
The ₹9.00 dividend provides a tangible return; investors should hold for the dividend record date. The clean audit report and subsidiary performance indicate strong operational control.
Sharda Cropchem Q3 FY26 PAT Surges 366% to ₹145 Cr; Declares ₹6 Interim Dividend
Sharda Cropchem reported a stellar Q3 FY26 performance with revenue growing 39% YoY to ₹1,289 crores, driven by a 48% surge in the agrochemical segment. Profitability saw a massive jump as PAT rose 366% to ₹145 crores, marking the company's highest-ever annual PAT within just nine months. Management has guided for continued momentum in FY27 with expected volume growth of 15% and revenue growth of 15-20%. The company remains net debt-free with a strong cash position of ₹826 crores and has declared an interim dividend of ₹6 per share.
முக்கிய அம்சங்கள்
Q3 FY26 Revenue grew 39% YoY to ₹1,289 crores, with Agrochemicals segment growing 48%PAT witnessed a massive 366% YoY growth to ₹145 crores, achieving record annual PAT in 9 monthsEBITDA margins improved to 19.1%, with management raising FY26 guidance to the 18-20% rangeWorking capital cycle improved significantly by 48 days compared to March 2025, now at 70 daysTotal product registrations reached 3,004, with an additional 1,076 applications in the pipeline
👀 கவனிக்க வேண்டியவை
Investors should note the strong volume recovery in Europe and Latin America and the company's ability to pass on costs. The robust registration pipeline and asset-light model support the management's optimistic 15-20% revenue growth guidance for FY27.
Sharda Cropchem Q3 PAT Jumps 366% to ₹145 Cr; Record 9M Profit; ₹6 Dividend Declared
Sharda Cropchem reported a stellar Q3 FY26 with revenue growing 39% YoY to ₹1,288.8 crore, driven by strong volume growth in Europe. Net profit skyrocketed by 366% YoY to ₹145.1 crore, while EBITDA margins expanded by 250 bps to 19.1%. Notably, the company has already achieved its highest-ever annual PAT within the first nine months of the fiscal year, totaling ₹362.3 crore. The company remains debt-free with a strong cash position of ₹826 crore and has declared an interim dividend of ₹6 per share.
முக்கிய அம்சங்கள்
Revenue grew 39% YoY to ₹1,288.8 Cr in Q3 FY26, with 9M FY26 revenue up 29% to ₹3,202.7 Cr.PAT for Q3 surged 366% YoY to ₹145.1 Cr; 9M FY26 PAT of ₹362.3 Cr is already the highest-ever annual profit for the company.EBITDA margins improved to 19.1% in Q3, up from 16.6% YoY, driven by volume growth and improved product mix.Europe agrochemical revenue grew by 123% YoY in Q3, significantly offsetting a 7% decline in the NAFTA region.Company declared an interim dividend of ₹6 per share and remains debt-free with ₹826 Cr in liquid investments.
👀 கவனிக்க வேண்டியவை
Investors should view this as a very strong performance characterized by significant margin expansion and record profits. The stock is likely to react positively to the earnings beat and the healthy interim dividend payout.
Sharda Cropchem Q3 FY26 PAT Surges 366% YoY to ₹145 Cr; Revenue Up 39%
Sharda Cropchem reported a robust performance for Q3 FY26, with total revenue growing 39% YoY to ₹1,289 crore, primarily driven by a 48% surge in the agrochemical segment. Net profit (PAT) witnessed a massive jump of 366% to ₹145 crore, supported by a 220 bps improvement in gross margins to 34.9%. The growth was largely fueled by the European market, which saw a 123% revenue increase in the agrochemical division. The company continues its asset-light strategy, investing ₹399 crore in capex during 9M FY26, mainly for product registrations.
முக்கிய அம்சங்கள்
Consolidated Revenue for Q3 FY26 grew 39% YoY to ₹1,289 Cr, with Agrochemicals contributing 89% of total sales.Net Profit (PAT) skyrocketed 366% YoY to ₹145 Cr, while EBITDA rose 59% to ₹246 Cr during the quarter.Gross Margins expanded by 220 basis points to 34.9% due to a favorable product mix and 14.5% volume growth in Agrochemicals.European agrochemical revenue more than doubled, growing 123% YoY to ₹654 Cr, offsetting a 7% decline in the NAFTA region.The company maintains a strong IP pipeline with 3,004 registrations and 1,076 additional applications pending globally.
👀 கவனிக்க வேண்டியவை
Investors should take note of the significant margin expansion and the company's successful penetration in the European market. The asset-light model continues to deliver high returns, making it a strong play in the global generic agrochemical space.
Sharda Cropchem Sets February 6, 2026, as Record Date for Interim Dividend
Sharda Cropchem Limited has officially fixed Friday, February 6, 2026, as the record date for its interim dividend for the financial year 2025-26. This date will be used to determine the eligibility of shareholders to receive the dividend payment. The announcement follows the company's compliance with SEBI Listing Obligations and Disclosure Requirements. While the specific dividend amount was not detailed in this filing, the establishment of a record date confirms a forthcoming cash payout to eligible investors.
முக்கிய அம்சங்கள்
Record date for interim dividend fixed as February 6, 2026Dividend pertains to the Financial Year 2025-26Announcement made in compliance with Regulation 42 of SEBI LODR RegulationsApplies to shareholders of NSE: SHARDACROP and BSE: 538666
👀 கவனிக்க வேண்டியவை
Investors seeking to receive the dividend should ensure they hold the stock before the ex-dividend date, which typically precedes the record date. Current shareholders must maintain their positions through the record date to qualify for the payout.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
